Insights on Embolic Protection, Repositioning, and Stroke: A Subanalysis of the RESPOND Study

Table 2

Neurological complications through 30 days after TAVR in patients with and without CEP use and valve repositioning.

Post-TAVR neurological complications	Overall population	Embolic protection use			Valve repositioning
		No CEP	CEP	value	No REPOS.	REPOS.	value
	N = 996	N = 904	N = 92		N = 683	N = 313
≤72 hr
Stroke/TIA	3.0% (30)	3.2% (29)	1.1% (1)	0.51	3.1% (21)	2.9% (9)	0.86
Stroke	2.5% (25)	2.7% (24)	1.1% (1)	0.72	2.5% (17)	2.6% (8)	0.95
Disabling stroke	1.8% (18)	2.0% (18)	0.0% (0)	0.40	1.6% (11)	2.2% (7)	0.49
Discharge
Stroke/TIA	3.7% (37)	3.9% (35)	2.2% (2)	0.57	3.8% (26)	3.5% (11)	0.82
Stroke	3.1% (31)	3.3% (30)	1.1% (1)	0.35	3.1% (21)	3.2% (10)	0.92
Disabling stroke	2.2% (22)	2.4% (22)	0.0% (0)	0.25	1.9% (13)	2.9% (9)	0.33
30-days
Stroke/TIA	3.9% (39)	4.1% (37)	2.2% (2)	0.57	3.8% (26)	4.2% (13)	0.79
Stroke	3.2% (32)	3.4% (31)	1.1% (1)	0.35	3.1% (21)	3.5% (11)	0.71
Disabling stroke	2.3% (23)	2.5% (23)	0.0% (0)	0.26	1.9% (13)	3.2% (10)	0.21